tbuckley/cabot-search huggingface dataset:
Abstract 17035: Inhibition of DNMT and HDAC6 Together Regulates Macrophage Polarization by FoxO1-HIF2α Signaling and Protects Endotoxemia-Induced Inflammation
Authors: Saheli Samanta, Zhigang Zhou, Sheeja Rajasingh, Kyley K Burkey, Rajasingh Johnson
Journal: Circulation (2018)

Introduction: Acute lung injury (ALI) is a common pulmonary disease caused by bacterial infection leading to an imbalance between pro-inflammatory and anti-inflammatory immune responses. Studies have shown that macrophage polarization (M1 and M2) during ALI plays a key role in regulating these responses. Hypothesis: We hypothesized that combined treatment with 5-Aza 2-deoxycytidine (Aza) + tubastatin A (TBA) would reduce inflammation and promote an anti-inflammatory M2 macrophage phenotype by regulating the HIF2α signaling pathway. Methods: To show the effect of Aza+TBA, lipopolysaccharide (LPS)-induced macrophages (RAW 264.7) were treated with either Aza (50nM), TBA n(750nM), or together (Aza+TBA) for 24 hours. The mRNA and protein expressions of FoxO1, HIF2α, NOS2 (M1), and CD206 (M2) were measured by qRT-PCR and Western analyses in lung tissue and macrophages. Results: Our results revealed that LPS induced macrophages showed an increased expression of NOS2 (M1) and decreased expression of Fizz-1 (M2) whereas the LPS-induced macrophages were treated with Aza+TBA showed decreased NOS2 (Fig. A) and increased Fizz-1 mRNA (Fig. B) and protein expressions. Furthermore, the LPS significantly decreased the mRNA and protein expressions of FoxO1 and HIF2α in macrophages. These expressions were significantly increased when the LPS-induced macrophages were treated with Aza +TBA (Fig. C) . These results suggest that Aza+TBA treatment together generates more M2 macrophages there by reducing the LPS-induced inflammatory responses. Conclusions: Overall, these data show the first time that the combinatorial treatment with Aza+TBA regulates macrophage cell polarization and abrogates LPS-induced inflammation through FoxO1-HIF2α signaling pathway. Thus, epigenetic modifiers may be potential therapeutic drugs for ALI. &lt;!--EndFragment--&gt;
Retraction notice to “30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)”
Authors: Y. Shi, L. Wu, X. Yu, P. Xing, J. Zhou, A. Wang, J. Shi, Y. Hu, Z. Wang, G. An, Y. Fang, S. Sun, C. Zhou, C. Wang, F. Ye, X. Li, J. Wang, M. Wang, Y. Liu, Y. Zhao
Journal: Annals of Oncology (2021)
Refinement and validation of the ItchyQoL using classical test theory and item response theory resulted in a reduction of the response categories from a 5‐point to a 3‐point scale
Authors: M. Gabes, C. Zeidler, S. Ständer, S. C. Chen, C. J. Apfelbacher
Journal: British Journal of Dermatology (2021)

The ItchyQoL is an itch-specific patient-reported outcome measure used to assess quality of life in patients with chronic pruritus (CP).We aimed to assess and extend the psychometric properties of the ItchyQoL using classical test theory (CTT) and item response theory (IRT).Item characteristic curves were analysed to investigate whether the response categories were functioning optimally. Confirmatory factor analyses were carried out on the ItchyQoL prior to and after rescoring of the response categories. We conducted a Rasch analysis for the ItchyQoL with revised response options and assessed the mean fit residuals in addition to the assumptions of unidimensionality and local independence.In total, 551 patients with CP from nine European countries completed the 22 items of the ItchyQoL. IRT analysis supported the revision of response options from five points to three. This revision was supported by excellent structural validity using CTT. The overall fit to the Rasch model was adequate. Unidimensionality was supported by the ItchyQoL overall scale and by the single subscales; however, local independence was violated in eight cases.We suggest a revision of the response categories of the ItchyQoL from a 5-point to a 3-point scale. When this revision was applied, the ItchyQoL showed excellent structural validity according to CTT and IRT/Rasch. The calculation of an overall ItchyQoL sum score is allowed.
Structural Variants at the<i>BRCA1/2</i>Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Authors: Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R. Grimes, Robert L. Hollis, C. Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson, Mairi Lennie, Trevor McGoldrick, Neil McPhail, Nadeem Siddiqui, Suzanne Dowson, Rosalind Glasspool, Melanie Mackean, Fiona Nussey, Brian McDade, Darren Ennis, Lynn McMahon, Athena Matakidou, Brian Dougherty, Ruth March, J. Carl Barrett, Iain A. McNeish, Andrew V. Biankin, Patricia Roxburgh, Charlie Gourley, Colin A. Semple
Journal: Clinical Cancer Research (2021)

Abstract Purpose: The abundance and effects of structural variation at BRCA1/2 in tumors are not well understood. In particular, the impact of these events on homologous recombination repair deficiency (HRD) has yet to be demonstrated. Experimental Design: Exploiting a large collection of whole-genome sequencing data from high-grade serous ovarian carcinoma (N = 205) together with matched RNA sequencing for the majority of tumors (N = 150), we have comprehensively characterized mutation and expression at BRCA1/2. Results: In addition to the known spectrum of short somatic mutations (SSM), we discovered that multi-megabase structural variants (SV) were a frequent, unappreciated source of BRCA1/2 disruption in these tumors, and we found a genome-wide enrichment for large deletions at the BRCA1/2 loci across the cohort. These SVs independently affected a substantial proportion of patients (16%) in addition to those affected by SSMs (24%), conferring HRD and impacting patient survival. We also detail compound deficiencies involving SSMs and SVs at both loci, demonstrating that the strongest risk of HRD emerges from combined SVs at both BRCA1 and BRCA2 in the absence of SSMs. Furthermore, these SVs are abundant and disruptive in other cancer types. Conclusions: These results extend our understanding of the mutational landscape underlying HRD, increase the number of patients predicted to benefit from therapies exploiting HRD, and suggest there is currently untapped potential in SV detection for patient stratification.
Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua
Authors: Nisha Nair, Dries De Wolf, Phuong Anh Nguyen, Quang Hong Pham, Ermira Samara, Jeff Landau, Grant E Blouse, Marinee K Chuah, Thierry VandenDriessche
Journal: Blood (2021)
Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology
Authors: Mandy Spaan, Alexandra W van den Belt-Dusebout, Cornelis B Lambalk, Hester H van Boven, Roel Schats, Marian Kortman, Frank J M Broekmans, Joop S E Laven, Evert J P van Santbrink, Didi D M Braat, Lucette A J van der Westerlaken, Ben J Cohlen, Astrid E P Cantineau, Jesper M J Smeenk, Minouche M van Rumste, Mariëtte Goddijn, Ron J T van Golde, Paul A M Meeuwissen, Carl J C M Hamilton, Gabriële M Ouwens, Miranda A Gerritsma, Michael Schaapveld, Curt W Burger, Flora E van Leeuwen
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background Long-term effects of assisted reproductive technology (ART) on ovarian tumor risk are unknown. Methods This nationwide cohort study comprises 30 625 women who received ovarian stimulation for ART in 1983-2000 and 9988 subfertile women not treated with ART. Incident invasive and borderline ovarian tumors were ascertained through linkage with the Netherlands Cancer Registry and the Dutch Pathology Registry until July 2018. Ovarian tumor risk in ART-treated women was compared with risks in the general population and the subfertile non-ART group. Statistical tests were 2-sided. Results After a median follow-up of 24 years, 158 invasive and 100 borderline ovarian tumors were observed. Ovarian cancer risk in the ART group was increased compared with the general population (standardized incidence ratio [SIR] = 1.43, 95% confidence interval [CI] = 1.18 to 1.71) but not when compared with the non-ART group (age- and parity-adjusted hazard ratio [HR] = 1.02, 95% CI = 0.70 to 1.50). Risk decreased with higher parity and with a larger number of successful ART cycles (resulting in childbirth, Ptrend = .001) but was not associated with the number of unsuccessful ART cycles. Borderline ovarian tumor risk was increased in ART-treated women compared with the general population (SIR = 2.20, 95% CI = 1.66 to 2.86) and with non-ART women (HR = 1.84, 95% CI = 1.08 to 3.14). Risk did not increase with more ART cycles or longer follow-up time. Conclusions Increased ovarian cancer risk in ART-treated women compared with the general population is likely explained by nulliparity rather than ART treatment. The increased risk of borderline ovarian tumors after ART must be interpreted with caution because no dose-response relationship was observed.
Exploiting bone niches: progression of disseminated tumor cells to metastasis
Authors: Aaron M. Muscarella, Sergio Aguirre, Xiaoxin Hao, Sarah M. Waldvogel, Xiang H.-F. Zhang
Journal: Journal of Clinical Investigation (2021)

Many solid cancers metastasize to the bone and bone marrow (BM). This process may occur even before the diagnosis of primary tumors, as evidenced by the discovery of disseminated tumor cells (DTCs) in patients without occult malignancies. The cellular fates and metastatic progression of DTCs are determined by complicated interactions between cancer cells and BM niches. Not surprisingly, these niches also play important roles in normal biology, including homeostasis and turnover of skeletal and hematopoiesis systems. In this Review, we summarize recent findings on functions of BM niches in bone metastasis (BoMet), particularly during the early stage of colonization. In light of the rich knowledge of hematopoiesis and osteogenesis, we highlight how DTCs may progress into overt BoMet by taking advantage of niche cells and their activities in tissue turnover, especially those related to immunomodulation and bone repair.
Making Care Fit in the Lives and Loves of Patients With Chronic Conditions
Authors: Marleen Kunneman, Victor Montori
Journal: JAMA Network Open (2021)

Mary E. Tinetti, MD; Darcé M. Costello, EdD, MPH, MBA; Aanand D. Naik, MD; Claire Davenport, MD, MS; Kizzy Hernandez-Bigos, BA; Julia R. Van Liew, PhD; Jessica Esterson, MPH; Eliza Kiwak, BA; Lilian Dindo, PhD
Government pledges £932m to cut emissions from hospitals and other public buildings
Authors: Elisabeth Mahase
Journal: BMJ (2021)

More than 400 projects across England will receive funding totalling £932m (€1.1bn; £1.3bn) to reduce carbon emissions from public buildings such as hospitals and schools, the government has said.

The Public Sector Decarbonisation Scheme was announced by business and energy secretary Kwasi Kwarteng on 17 March, and will fund low carbon heating systems, such as heat pumps, as well as energy efficiency measures like insulation and LED lighting. …
Drug-Eluting vs Bare-Metal Stents for Percutaneous Coronary Intervention—Reply
Authors: Irbaz Hameed, Mario Gaudino
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 14875: Chronic Obstructive Pulmonary Disease Negatively Affects In-hospital Outcomes in Patients With Takotsubo Cardiomyopathy
Authors: Pengyang Li, Catherine Teng, Mark Kranis, Peng Cai, Qiying Dai, Su Pan, Richard A Dixon, Qi Liu
Journal: Circulation (2020)

Introduction: Chronic obstructive pulmonary disease (COPD) is a known comorbidity of takotsubo cardiomyopathy (TCM), and COPD exacerbation is a potential trigger of TCM. The association between COPD and in-hospital outcomes and complications in TCM patients is not well established. Aim: We aimed to assess the effect of COPD on hospitalized patients with a primary diagnosis of TCM. Methods: Using the latest National Inpatient Sample from 2016-2017, we conducted a retrospective cohort study in patients with a primary diagnosis of TCM with or without COPD. The diagnosis was identified by the ICD-10-CM coding system. We identified 3,139 patients admitted with a primary diagnosis of TCM; 684 of those patients also had a diagnosis of COPD. We performed propensity score matching in a 1:2 ratio (n=678 patients, matched COPD group; n=1,070, matched non-COPD group) and compared in-hospital outcomes and complications between TCM patients with and without a COPD diagnosis. Results: Before matching, the COPD group had worse outcomes compared with the non-COPD group in inpatient death (2.9% vs. 1.3%, p=0.006), length of stay (LOS) (4.02±2.99 days vs. 3.27±3.39 days, p&lt;0.001), hospitalization costs ($55,242.68±47,637.40 vs. $48,316.97±47,939.84, p=0.001), and acute respiratory failure (ARF) (22.5% vs. 7.7%, p&lt;0.001), respectively. After propensity score matching, the matched COPD group, compared with the matched non-COPD group, had a higher inpatient mortality rate (2.9% vs.1.0%, p=0.005), longer LOS (4.02±3.00 days vs. 3.40±3.54 days, p&lt;0.001), higher hospitalization costs ($55,409.23±47,809.13 vs. $44,6469.60±42,209.10, p&lt;0.001), and a higher incidence of ARF (22.6% vs. 8.2%, p&lt;0.001) and cardiogenic shock (5.6% vs. 3.3%, p=0.024), respectively. Conclusions: Patients who are hospitalized for TCM and have COPD have higher rates of inpatient mortality, ARF, and cardiogenic shock, as well as a longer LOS and a higher cost of stay than TCM patients without COPD. Prospective studies are warranted to examine the effect of early intervention or treatment of COPD on short and long-term outcomes of TCM.
Acute onset dysphagia and neck pain after eating
Authors: Edward Balai, Hannah Nieto, Neil Molony
Journal: BMJ (2021)

A woman in her 40s presented to the emergency department late in the evening with dysphagia and discomfort in her throat at the level of the suprasternal notch. Her symptoms had started while she was eating a pork chop for dinner. She was able to swallow saliva and was not drooling, but any attempt to swallow fluids resulted in severe pain and immediate regurgitation. Her airway was assessed and found to be clear; she was able to speak in full sentences, and no change to her voice was discerned. She had no stridor and no difficulty breathing.

Observations on admission were

Nothing remarkable was seen on examination of the patient’s neck and oral cavity. The patient was otherwise fit and well, …
Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication
Authors: Haitao Guo, Qi Wang, Khader Ghneim, Li Wang, Elena Rampanelli, Elizabeth Holley-Guthrie, Liang Cheng, Carolina Garrido, David M. Margolis, Leigh A. Eller, Merlin L. Robb, Rafick-Pierre Sekaly, Xian Chen, Lishan Su, Jenny P.-Y. Ting
Journal: Nature Immunology (2021)
"Bridge" neoadjuvant endocrine therapy for early stage breast cancer patients during COVID-19 at an academic hospital in NYC: Lessons learned
Authors: C. Cen, F. Schnabel, S. Adams, M. Plasilova, J. Yeh, M. Meyers, J. Speyer, E. Belenkov, M. Kwa, Y. Novik, E. Katz, A. Guth
Journal: Cancer Research (2021)
Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial
Authors: Christina J Sperna Weiland, Xavier J N M Smeets, Wietske Kievit, Robert C Verdonk, Alexander C Poen, Abha Bhalla, Niels G Venneman, Ben J M Witteman, David W da Costa, Brechje C van Eijck, Matthijs P Schwartz, Tessa E H Römkens, Jan Maarten Vrolijk, Muhammed Hadithi, Annet M C J Voorburg, Lubbertus C Baak, Willem J Thijs, Roy L van Wanrooij, Adriaan C I T L Tan, Tom C J Seerden, Yolande C A Keulemans, Thomas R de Wijkerslooth, Wim van de Vrie, Peter van der Schaar, Sven M van Dijk, Nora D L Hallensleben, Ruud L Sperna Weiland, Hester C Timmerhuis, Devica S Umans, Jeanin E van Hooft, Harry van Goor, Hjalmar C van Santvoort, Marc G Besselink, Marco J Bruno, Paul Fockens, Joost P H Drenth, Erwin J M van Geenen
Journal: The Lancet. Gastroenterology & hepatology (2021)
Utilization of health information technology among skin cancer patients: A cross-sectional study of the National Health Interview Survey from 2011 to 2018
Authors: Thomas B. Cwalina, Tarun K. Jella, David X. Zheng, Raghav Tripathi, Melissa A. Levoska, Jeremy S. Bordeaux, Jeffrey F. Scott
Journal: Journal of the American Academy of Dermatology (2021)
P76.88 Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs
Authors: J. Ma, S.H. Tan, D. Yin, A. Tran, D. Tan, M. Ang, A. Takano, K.H.T. Lim, R. Kanesvaran, A. Jain, T. Rajasekaran, E. Tan, D.W. Lim, Q.S. Ng, W. Tan
Journal: Journal of Thoracic Oncology (2021)
The relationship between screen time and mental health in young people: A systematic review of longitudinal studies
Authors: Samantha Tang, Aliza Werner-Seidler, Michelle Torok, Andrew J. Mackinnon, Helen Christensen
Journal: Clinical Psychology Review (2021)

An increase in time spent on screen-based technologies has been suggested to underlie recent increases in mental health problems among young people. However, this hypothesis has primarily been based on the findings of cross-sectional studies. The aim of the current review was to provide a comprehensive overview of longitudinal studies examining the relationship between screen time and internalising mental health symptoms. PsycINFO, PubMed/Medline and EMBASE were systematically searched for articles published up to August 2020. Thirty-five studies, with sample sizes ranging from 126 to 12,866 participants, met inclusion criteria. The association between screen time and subsequent depressive symptoms was found to be small to very small in size. There was limited evidence of any reverse association between depressive symptoms and subsequent screen time. The association between screen time and depressive symptoms varied between different devices and uses. In contrast to depressive symptoms, evidence to support longitudinal associations between screen time and other internalising mental health symptoms, including anxiety, self-esteem, and general internalising problems, was lacking. Together, these results suggest that the impact of increased screen time on the prevalence of mental health problems among young people is likely to be negligible or small. Further longitudinal studies that examine screen content and motivations underlying screen use are required to better discern any relationship between screen time and internalising mental health symptoms.
Mitochondria-Targeted Effects of Water-Soluble Polyol-Methanofullerenes on Human Whole Blood Platelets, Lymphocytes and Granulocytes Ex Vivo
Authors: Gulzada Tarasova, Natalia Kalacheva, Guzel Fazleeva, Valentina Gubskaya, Albert Rizvanov, Georgi Cherepnev
Journal: Blood (2017)
P47.08 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Clinical Benefit of Immunotherapy in Small-Cell Lung Cancer
Authors: X. Hu, M. Yuan, Y. Feng, T. Zhang, L. Zhang, G. Dong, H. Zhu, Y. Liu, P. Xing, H. Wang, B. Li, Y. Shi, R. Chen, X. Xia
Journal: Journal of Thoracic Oncology (2021)
Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer
Authors: Jianhua Wang, Jincheng Wang, Jinlu Dai, Younghun Jung, Chuen-Long Wei, Yu Wang, Aaron M. Havens, Phillip J. Hogg, Evan T. Keller, Kenneth J. Pienta, Jacques E. Nor, Cun-Yu Wang, Russell S. Taichman
Journal: Cancer Research (2021)

This article (1) is being retracted at the request of the authors. The images used in the second and third panels of CXCR4 siRNA in Fig. 1B were duplicated from the first and second panels of PC3-control cells in Fig. 1B of a previously published article that has since been retracted (2). The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.A copy of this retraction notice was sent to the last known email addresses for 13 of the 13 authors. Ten authors (Jinlu Dai, Younghun Jung, Yu Wang, Aaron M. Havens, Phillip J. Hogg, Evan T. Keller, Kenneth J. Pienta, Jacques E. Nor, Cun-Wu Wang, Russell Taichman) agreed to the retraction; three authors (Jianhua Wang, Jincheng Wang, and Chuen-Long Wei) did not respond.
MA13.09 Heterogeneous Genomic Evolution and Immune Microenvironments in Metastatic Lung Cancer
Authors: W. Tang, M. Wu, H. Bao, Y. Zhang, J. Zhang, J. Su, J. Lin, F. Xu, J. Chen, R. Fu, Y. Chen, T. Wu, X. Wu, Y.W. Shao, S. Dong, Q. Nie, X. Yang, Y. Wu, W. Zhong
Journal: Journal of Thoracic Oncology (2021)
P57.02 High Frequency of Heterozygous Truncating Germ-Line Mutations in DNA Repair Genes in Young-Onset and/or ALK-Rearranged Lung Cancer Patients
Authors: E. Imyanitov, A. Sokolenko, A. Iyevleva, V. Tiurin, T. Sokolova, A. Ivantsov, N. Mitiushkina, S. Orlov, E. Levchenko, I. Bizin
Journal: Journal of Thoracic Oncology (2021)
FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study
Authors: C. Zhou, J. He, C. Su, W. Liang, S. Xu, L. Wu, X. Fu, X. Zhang, D. Ge, C. Chen, W. Mao, L. Xu, G. Shao, W. Li, B. Hu, C. Chen, J. Fu, Z. Wang, Z. Jianying, Y. Huang, H. Ma, Y. Liu, F. Ye, J. Hu, J. Zhao, X. Liu, Z. Liu, Z. Wang, R. Xu, Z. Xiao, T. Gong, W. Lin, X. Li, L. Ding, L. Mao
Journal: Journal of Thoracic Oncology (2021)